World News

AstraZeneca plans to reinvest most of the savings in research and development, although the programme is expected to incur up to US$2 billion in one-time restructuring costs over three years.

The clinical-stage biotechnology company will also use the proceeds to expand its research pipeline across autoimmune diseases, immunology, neurological disorders and oncology.

The new sterile manufacturing plant will complement Bracco’s existing production operations in Europe, Asia and Canada, expanding its global manufacturing network.

The association also promotes research with potential for practical applications, including developing new knowledge, technologies, and products that could support cancer diagnosis and treatment.

The facility operates in accordance with requirements established by the US Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA).

Operated by OMRON HEALTHCARE MANUFACTURING INDIA Pvt. Ltd., the approximately 24,000-square-metre factory is located at ORIGINS by Mahindra and has five production lines serving the Indian market.

The financing attracted existing investors Deerfield Management, Canaan, Droia Ventures, EcoR1, Euclidean Capital and Regeneron Ventures.

Enthorin will receive an upfront payment and an option exercise fee, alongside milestone payments tied to development, regulatory and commercial progress.

Formation Bio will serve as the fund’s general partner through a wholly owned subsidiary and has committed its own capital alongside external limited partners.

Built on the Philips Azurion image-guided therapy platform, UniGuide lets clinicians access preprocedural imaging information within the same workflow they use to guide treatment.